

ISSN: 0976-3031

*International Journal of Recent Scientific
Research*

Impact factor: 5.114

**ANTIPHOSPHOLIPID AUTOANTIBODIES TESTING IN
WOMEN WITH UNEXPLAINED INFERTILITY AND
RECURRENT FIRST TRIMESTER ABORTION**



Nisreen K.Al-Bezrah

Volume: 6

Issue: 10

**THE PUBLICATION OF
INTERNATIONAL JOURNAL OF RECENT SCIENTIFIC RESEARCH**

<http://www.recentscientific.com>

E-mail: recentscientific@gmail.com



RESEARCH ARTICLE

ANTIPHOSPHOLIPID AUTOANTIBODIES TESTING IN WOMEN WITH UNEXPLAINED INFERTILITY AND RECURRENT FIRST TRIMESTER ABORTION

Nisreen K.Al-Bezrah

Department of Obstetrics and Gynecology, Faculty of Medicine, Taif, Saudi Arabia

ARTICLE INFO

Article History:

Received 05th July, 2015
Received in revised form
08th August, 2015
Accepted 10th September, 2015
Published online 28st
October, 2015

ABSTRACT

A prospective study was carried assessing the presence and evaluating the pathological role of antiphospholipid auto-antibodies (aPLA) in women suffering from unexplained infertility or recurrent first trimester abortion. It was carried out Between June 2013 and December 2014, on 20 women with unexplained fertility (group A), 20 women with recurrent first trimester abortion (group B), compared to 20 healthy women as control (group C). It was found that IgA, IgM and IgG levels were significantly higher in group A, B when compared to group C. Lupus anticoagulant (LA), tested by the activated partial thromboplastin time (APTT), was prolonged in 4 (20%) group A and 3 (15%) cases in group B. So it was concluded that reproductive performance may be affected by the abnormal presence of antiphospholipid auto-antibodies.

Key words:

Antiphospholipid antibodies,
unexplained infertility, recurrent
first trimester abortion

Copyright © Nisreen K.Al-Bezrah. 2015, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

The investigation of causes of infertility and fetal loss are begging to deal increasingly with immunological factors, and in particular, with the autoimmunity (Radojic *et al*, 2004). Antiphospholipid antibodies (aPLA) are immunoglobulin that interfere with one or more phospholipid-dependent coagulation tests which lead to thromboembolic predisposition. Patients with persistent elevated results are at risk of arterial and venous thrombosis, gestational loss and other complications (Lockshin *et al*, 1990). It has become apparent that reproductive success may be affected by the presence of abnormal aPLA (Car *et al*, 2007). The association between recurrent pregnancy loss and autoimmune diseases has been recognized since Nilsson *et al*, 2004., who reported the association between the presence aPLA and adverse pregnancy outcomes.

Younis *et al*, 2000. reported that the presence of aPLA which included the lupus anticoagulant (LAC) and anticardiolipin antibody (ACL) were the main cause recurrent abortion in apparently healthy women and the mechanism of action is not completely clear. Mc *et al*, 2006. has reported that certain aPLA interferes in very early pregnancy, at the stage of fetal implantation, by imbedding normal reproductive event. These miscarriages or implantation failures may be related to pathological mechanism causing recurrent abortion, which is commonly diagnosed as infertility (Birkenfeld A *et al*, 1994). It

has been underlined that in addition to recurrent pregnancy loss, the autoimmune system may be involved in other reproductive processes such as endometriosis, unexplained infertility and in-vitro fertilization (IVF) failure (Geirger *et al*, 1973). However, despite the current interest in immunological factors leading to unexplained infertility, the relationship between aPLA, which can be immunoglobulin G (IgG), IgM or IgA classes, and reproductive performance is still controversial (Balasch *et al*, 1996).

The aim of this study was to assess the occurrence of antiphospholipid antibodies in women suffering from unexplained infertility or recurrent first trimester abortion to evaluate their pathogenic role in these disorders.

PATIENTS AND METHODS

This prospective study was conducted in Obstetrics and Gynecology Department, King Abdul Aziz Specialist Hospital (500 beds), Taif, Saudi Arabia. Between June 2013 and December 2014, 60 patients were recruited from women attending the gynecological, infertility and recurrent pregnancy loss clinics. All cases were subjected to the following: a full clinical history, medical and gynecological examinations to exclude cases that may invalidate the results of immunoglobulin. Cases included in the study have been classified into three groups

*Corresponding author: **Nisreen K.Al-Bezrah**

Department of Obstetrics and Gynecology, Faculty of Medicine, Taif, Saudi Arabia

Group A: This group. Comprised 20 women with unexplained infertility. Their ages ranges from 22 to 34 years with a duration of marriage ranging between 4 to 10 years. All patients in this group had experienced a variable period of infertility and had undergone an intensive infertility evaluation without evidence of any diagnostic abnormality. The fertility evaluation of women included confirmation of ovulation, normal hysterosalpingogram, normal laparoscopy findings, and negative cervical cultures and in phase endometrial biopsy specimen and the male partners were having at least two normal seminograms.

Group B: Included 20 patients who had recurrent first trimester abortion with no previous history of live births for at least two years. Their ages ranged from 22 to 35 years. Repeated first trimester pregnancy loss is defined as the occurrence of three or more clinically recognized losses before 12 weeks from the last menstrual period which are consecutive and spontaneous (Wilcox *et al* ,1988). Cytogenetic analysis revealed normal karyotyping results for all cases in this group.

Group C: Included 20 fertile women who were healthy without history of autoimmune disease or pregnancy loss.

METHODS

Blood sampling processing

Blood samples were obtained for activated partial thromboplastic time, dilute Russell viper venom time and anticardiolipin antibody (IgA, IgM, and IgG). Blood samples were divided equally and put in 2 test tubes, the first was planned for serum testing and the second was citrated tube for full separated plasma. An activated partial thromboplastic time test was done immediately on aliquot puff plasma. The remaining plasma was frozen at -70°C for subsequent testing for dilute Russell viper venom time. Serum was separated from the cell mass and frozen at -70°C to determine the anticardiolipin antibody isotypes by enzyme-linked immunosorbent assay (ELISA).

Evaluation of partial thromboplastic time (APTT)

Platelet-poor plasma was incubated for 3 minutes at 37°C with activated partial thromboplastin time reagent (Auto-aPT; Organ Teknika, Durham, North Carolina) and the time to clot formation was measured by standard procedure (Coagumate/2000, Organ Teknika). The activated partial thromboplastin time test was preformed according to the method of Proctor and Rppaport, 1966 . A value that was 2 or more standard deviation above the mean for healthy controls was considered abnormal.

Evaluation of Dilute Russell Viper Venom Time

Platelet-poor plasma (100 μL) was added to a mixture of dilute phospholipid (1/400 dilution Rabbit Brain Cephalin; Sigma Chemicals, St. Louis, Missouri) and 200 μL Russell's Viper Venom (1/40 000 dilution of 1 mg crude venom; Sigma Chemicals). After 1 minute, 100 μL calcium ions (0.25

mmol/L) were added and the time for clot formation was determined. The established range, based on frozen samples from 50 healthy, nonsmoking, non pregnant persons of both sexes taking no medications was 26 to 32 seconds (mean \pm 2 SD).

Evaluation of Anticardiolipin antibodies

Anticardiolipin antibodies (IgA, IgG and IgM) were measured in duplicate using the commercial anticardiolipin antibody ELISA kit (REAADS Medical Products, Westminster, Colorado). Briefly, serum samples, control sera, and calibrator sera were diluted 1:50 in sample diluent (0.01 mol/L phosphate-buffered saline, pH 7.4, containing 10% bovine serum). One hundred μL of diluted serum was incubated in duplicate wells of 96-well plates coated with beef heart cardiolipin (diphosphatidyl glycerol) for 15 minutes at room temperature. The serum was removed and the wells were washed four times with phosphate-buffered saline. One hundred μL of a prediluted horseradish peroxidase-conjugated goat antihuman IgG or IgM or Rabbit anti-IgA was added to each well and incubated for 15 minutes at room temperature. After washing, 100 μL of a 1:1 substrate mixture of tetramethylbenzidine and H_2O_2 was added to the micro wells and incubated for 10 minutes at room temperature. Color development was stopped by addition of 100 μL of 2.5 N H_2SO_4 and the absorbance at 450 nm was measured using an Emax micro titer plated reader (Molecular Devices, Menlo Park, California). The values of anticardiolipin antibody activity for each sample were calculated from calibrator sera according to the manufacturer's instruction. This assay was standardized relative to the international reference preparations (original 1984 set) obtained from the Anti-Phospholipid Standardization Laboratory, University of Louisville, Louisville, Kentucky. The normal cutoff value of the assay (23 units IgG, 11 units IgM) was defined as the mean IgG or IgM units plus two standard deviations of a healthy patient group. Immunoglobulin A anticardiolipin antibody activity was assessed using REAADS IgA anticardiolipin antibody test kit. A positive level (22 units) was defined as the mean plus three standard deviations of a healthy patient group.

Statistical Analysis

A statistical analysis was performed using the unpaired student's t-test. The relationship between the parameters analyzed was assessed using the linear regression method. Data were presented as mean \pm SD, unless otherwise indicated. $P < 0.05$ was considered to be statistically significant.

RESULTS

This study was carried out on 40 patients with either unexplained infertility or recurrent first trimester abortion and 20 and 20 age and sex matched normal fertile cases as control group. Twenty women with unexplained infertility (group A), their ages ranged from 22 to 34 years with a mean of 27.4 ± 3.12 years and a duration of marriage ranged from 4 to 8 years with a mean of 6.1 ± 1.2 . Twenty women with recurrent first trimester abortion (group B), their ages ranged from 22 to 36 years with

a mean of 29.4±4.3 years and the mean number of pregnancy loss in this group was 3.25±1.2. Twenty healthy fertile women without a history of autoimmune diseases (control group), their ages ranged between 19 to 30 years with a mean of 25.4±2.7 years. The result of our study showed that in group A the serum IgA, IgM and IgG levels were significantly higher than those of group C (control group) (Table 1). In group B the serum IgA, IgM and IgG levels were significantly higher than those of group C (Table 2). The activated partial thromboplastin time was higher in group A than in group C but with no significant difference (Table 3), but it was significantly higher in group B than in group C (Table 4). Table (5) summarizes the total number and percentage of abnormal tests in the studied groups. It shows that VDRL was positive in 2 patients of group A (10%) and in 3 patients in group B (15%) but it was negative in group C. While APTT was abnormally prolonged in 4 (20%) cases in group A and 3 (10%) cases in group B compared to normal test in the control group.

Table 1 Comparison between group A and group C as regard to IgA, IgM and IgG.

	Group A		Group C		P
	Mean	SD	Mean	SD	
IgA(gm/L)	2.27	±0.23	2.06	±0.14	<0.01
IgM(mg/L)	2.32	±0.18	1.91	±0.2	<0.001
IgG(gm/L)	14.5	±0.87	13.6	±0.63	<0.001

IgA =Immunoglobulin A, IgM =Immunoglobulin M, IgG =Immunoglobulin G, P<0.05 = Significant.

Table2 Comparison between group B and Group C as regard to IgA, IgM and IgG.

	Group B		Group C		P
	Mean	SD	Mean	SD	
IgA(gm/L)	2.61	±0.32	2.26	±0.2	<0.001
IgM(mg/L)	2.88	±0.46	1.36	±0.33	<0.001
IgG(gm/L)	15.34	±1.38	14.11	±0.77	<0.01

IgA =Immunoglobulin A, IgM =Immunoglobulin M, IgG =Immunoglobulin G, P<0.05 = Significant.

Table3 Activated partial thromboplastin time in group A versus group C

	Group A (No. 20)		Group C (No. 20)		P
	Mean	SD	Mean	SD	
APTT (seconds)	38.11	±3.89	36.26	±1.53	> 0.05

APTT =Activated Thromboplastin Time, P = Non significant

Table4 Activated partial thromboplastin time in group B versus group C

	Group B (No. 20)		Group C (No. 20)		P
	Mean	SD	Mean	SD	
APTT (seconds)*	41.76	±2.26	38.9	±1.08	<0.001

APTT =Activated Thromboplastin Time, P<0.05 = Significant

Table5. Frequency of positive ant phospholipid antibody test results in the studied groups.

	Group A (No.20)		Group B (No. 20)		Group C (No. 20)		P	
	Abnormal Tested no.	Abnormal Test (%)	Abnormal Tested no.	Abnormal Test (%)	Abnormal Tested no.	Abnormal Test (%)	A vs C	B vs C
	IgA(gm/L)	9*	45%	11	55%	1	5%	0.003
IgM(mg/L)	15	75%	16	80%	0	0%	<0.001	<0.001
IgG(gm/L)	17	85%	18	90%	2	10%	<0.001	<0.001
VDRL antibodies	2	10%	3	15%	0	0%	<0.001	<0.001
APTT (seconds)	4	20%	3	15%	0	0%	0.03	0.07

IgA =Immunoglobulin A, IgM =Immunoglobulin M, IgG =Immunoglobulin G, VDRL = Venereal Disease Research Laboratory, APTT = Activated Thromboplastin Time.

There was a difference between the number of the patients showing abnormal test results in the study and control groups. The difference was highly significant except APTT there was no significant difference between them.

DISCUSSION

In the study, we aimed at detection aPLA in the sera of first trimester abortion and compare them with control group without history of autoimmune disease to find the relation between these auto-antibodies and an abnormal reproductive performance. This study has confirmed the association between the presence of abnormal auto-antibodies and the repeated pregnancy wastage and unexplained infertility, hence the importance of their testing for assessment in risky patients. This finding is in agreement with that reported by Lubbe *et al.* and Branch *et al.*

In recent years various types of reproductive failure have come to be considered as having an immune component. Immunologic effects are important at many levels in the reproductive process, including fertilization, implementation and the development of the placenta (Billingham *et al.*, 1981). Ant phospholipid antibodies have been particularly associated with fetal loss and there is primarily evidence that auto-antibody profile can be correlated with reproductive failure. However, despite the current interest in immunological factors leading to unexplained infertility, the relationship between aPLA and reproductive performance is still controversial (Balasch *et al.*, 1996). The present results concern the determination of organ-specific aPA in fertile and infertile women. The results show an increased incidence of aPLA antibodies in the group with unexplained infertility, which is in agreement with other published data (Roussev *et al.*, 1996).

The results of the current study showed that group A and B patients exhibited an unusual incidence of gammopathies. Serum IgA, IgG and IgM levels against phospholipids in both groups were found to be higher than their levels in control group. This result is in agreement with that reported by Gleicher *et al.* who found unusual patients with unexplained infertility and 11 out of 24 patients with unexplained pregnancy wastage. The same result was reported by Kutteh *et al.*

However, Fisch *et al.* affirmed that the increased circulating aPA level in fertile patients may be related to IVF treatment, however, recently, it has been suggested that increased circulating aPA concentrations are no dependent on the treatment but must be considered in relation to the infertile state (Royburt *et al.*, 1996). The rationale for the role of aPA in infertility may be merely speculative (Battaglia *et al.*, 1998).

Proposed theories include inhibition of prostacyclin ratio (Bouvier *et al*, 2014), an increase in platelet activation (Harris *et al*, 1985). and a decrease in the activation of the antithrombotic action of protein C (Cariou *et al*,1998) Furthermore, it has been shown that the attachment of aPA to surface phospholipids on the trophoblast may result in direct cellular injury, with inhibition of the cytotrophoblastic conversion to syncytiotrophoblast (Kowalik *et al*, 1997). Lupus anticoagulant antibodies could be detected by prolongation of the activated partial thromboplastin time (Gharavi *et al*, 1987). Although the cause of fetoplacental pathology in the presence of lupus anticoagulant phenomenon is still unknown, it is likely that there is a thrombotic tendency involving the decidual and placental blood vessels which is responsible for the infarction and necrosis that have been described in these cases (Gupta *et al*, 2007). In the present study the mean APTT of cases in group A and B was significantly higher than in control group. Gleicher *et al*. studied lupus anticoagulant by APTT values which were abnormal in only 3 out of 26 patients with unexplained infertility and 2 out of 24 patients with pregnancy wastage. Rote *et al*. found that APTT values were abnormally prolonged in 45 out of 47 patients with unexplained pregnancy wastage. However, Wong *et al*. reported that 7 out of 35 patients with unexplained pregnancy wastage had prolonged partial thromboplastin time. In the present study VDRL was positive in only 2 patients (10%) in group A and in 3 patients (15%) in group B and it was negative in all cases of group C. This result is in agreement with that of Cowchock *et al*. who found 2 cases with false positive VDRL result out of 61 cases with unexplained losses. Conclusion, the role of antiphospholipid autoantibodies remains to be elucidated, but their importance in unexplained infertility or recurrent first trimester abortion is clear, providing an approach for therapeutic intervention. Exploring the role of aPL in reproduction may provide a novel strategy for better understanding maternal-fetal interactions in the uterus. Additional studies are needed to develop scientific rationale for the effect of antiphospholipid antibodies on the reproductive performance of women and if there is a beneficial effect of treating.

References

- Balasz, J., Creus, M., Fábregues, F., Reverter, J. C., Carmona, F., Tàssies, D., ... & Vanrell, J. A. (1996). Pregnancy: Antiphospholipid antibodies and human reproductive failure. *Human reproduction*, 11(10), 2310-2315.
- Balasz, J., Creus, M., Fábregues, F., Reverter, J. C., Carmona, F., Tàssies, D., ... & Vanrell, J. A. (1996). Pregnancy: Antiphospholipid antibodies and human reproductive failure. *Human reproduction*, 11(10), 2310-2315.
- Battaglia, C., Sgarbi, L., Salvatori, M., Maxia, N., Gallinelli, A., & Volpe, A. (1998). Increased anticardiolipin antibodies are positively related to the uterine artery pulsatility index in unexplained infertility. *Human reproduction*, 13(12), 3487-3491.
- Billingham, R. E., & Head, J. R. (1981). Current trends in reproductive immunology: an overview. *Journal of reproductive immunology*, 3(5), 253-265.
- Birkenfeld, A., Mukaida, T., Minichiello, L., Jackson, M., Kase, N. G., & Yemini, M. (1994). Incidence of autoimmune antibodies in failed embryo transfer cycles. *American Journal of Reproductive Immunology*, 31(2-3), 65-68.
- Branch, D. W., Scott, J. R., Kochenour, N. K., & Hershgold, E. (1985). Obstetric complications associated with the lupus anticoagulant. *New England Journal of Medicine*, 313(21), 1322-1326.
- Cariou, R., Tobelem, G., Bellucci, S., Soria, J., Soria, C., Maclouf, J., & Caen, J. (1988). Effect of lupus anticoagulant on antithrombotic properties of endothelial cells--inhibition of thrombomodulin-dependent protein C activation. *Thrombosis and haemostasis*, 60(1), 54-58.
- Carp, H, J. A., Shoenfeld Y. (2007) . Anti-phospholipid antibodies and infertility. *Clinical reviews in allergy & immunology* , 32.2: 159-161.
- Cowchock, S., Smith, J. B., & Gocial, B. (1986). Antibodies to phospholipids and nuclear antigens in patients with repeated abortions. *American journal of obstetrics and gynecology*, 155(5), 1002-1010.
- Fisch, B., Rikover, Y., Shohat, L., Zurgil, N., Tadir, Y., Ovadia, J., ... & Yron, I. (1991). The relationship between in vitro fertilization and naturally occurring antibodies: evidence for increased production of antiphospholipid autoantibodies. *Fertility and sterility*, 56(4), 718-724.
- Geirger N, Pratt D and Dudkiewicz A. What we really know about autoantibody abnormalities and reproductive failure: A Critical review. *Autoimmunity* 1973;16:115-140.
- Geirger N., Pratt D. and Dudkiewicz A.(1973). What we really know about autoantibody abnormalities and reproductive failure. *A Critical review of Autoimmunity*, 16,115-140.
- Gharavi, A. E., Harris, E. N., Asherson, R. A., & Hughes, G. R. (1987). Anticardiolipin antibodies: isotype distribution and phospholipid specificity. *Annals of the rheumatic diseases*, 46(1), 1-6.
- Gleicher, N., El-Roeiy, A., Confino, E., & Friberg, J. (1989). Reproductive failure because of autoantibodies: unexplained infertility and pregnancy wastage. *American journal of obstetrics and gynecology*, 160(6), 1376-1385.
- Gupta, S., Agarwal, A., Banerjee, J., & Alvarez, J. G. (2007). The role of oxidative stress in spontaneous abortion and recurrent pregnancy loss: a systematic review. *Obstetrical & gynecological survey*, 62(5), 335-347.
- Harris, E. N., Gharavi, A. E., Hegde, U., Derue, G., Morgan, S. H., Englert, H., ... & Hughes, G. R. V. (1985). Anticardiolipin antibodies in autoimmune thrombocytopenic purpura. *British journal of haematology*, 59(2), 231-234.
- Hertz-Picciotto, I., Samuels, S. J., Wilcox, A. J., Weinberg, C. R., & O'Connor, J. F. (1988). Incidence of Early Loss of Pregnancy. *N Engl J Med*, 1988(319), 1483-1484.
- Kowalik, A., Vichnin, M., Liu, H. C., Branch, W., & Berkeley, A. S. (1997). Midfollicular anticardiolipin and

- antiphosphatidylserine antibody titers do not correlate with in vitro fertilization outcome. *Fertility and sterility*, 68(2), 298-304.
- Kutteh, W. H., Lyda, E. C., Abraham, S. M., & Wacholtz, M. C. (1993). Association of anticardiolipin antibodies and pregnancy loss in women with systemic lupus erythematosus. *Fertility and sterility*, 60(3), 449-455.
- Lockshin, M. D., Qamar, T., & Levy, R. A. (1990). Anticardiolipin and related antibodies: thrombosis and fetal death. *Pregnancy, Autoimmunity and Connective Disorders*. Oxford University Press, New York, 185-211.
- Lubbe, W. F., Butler, W. S., Palmer, S. J., & Liggins, G. C. (1984). Lupus anticoagulant in pregnancy. *BJOG: An International Journal of Obstetrics & Gynaecology*, 91(4), 357-363.
- McIntyre, J. A. (2003). Antiphospholipid Antibodies in Implantation Failures*. *American Journal of Reproductive Immunology*, 49(4), 221-229.
- Proctor, R. R., & Rapaport, S. I. (1961). The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. *American Journal of Clinical Pathology*, 36, 212.
- Radojić, L., Marjanović, S., Viovać, L., & Kataranovski, M. (2004). Anticardiolipin antibodies in women with unexplained infertility. *Physiol. Res*, 53, 91-96.
- Rote, N. S., Johnson, D. D., & Branch, D. W. (1990). Antiphospholipid antibodies and recurrent pregnancy loss: correlation between the activated partial thromboplastin time and antibodies against phosphatidylserine and cardiolipin. *American journal of obstetrics and gynecology*, 163(2), 575-584.
- Roussev, R. G., Kaider, B. D., Price, D. E., & Coulam, C. B. (1996). Laboratory evaluation of women experiencing reproductive failure. *American Journal of Reproductive Immunology*, 35(4), 415-420.
- Sciascia, S., Hunt, B. J., Talavera-Garcia, E., Lliso, G., Khamashta, M. A., & Cuadrado, M. J. (2015). The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. *American journal of obstetrics and gynecology*.
- Wilcox, A. J., Weinberg, C. R., O'Connor, J.F., Baird, D.D., Schacterer, J.P., Canfield, R.E., & Nisula, B.C. (1988). In Cidence of ears loss of Pregnancy New England Journal of Medicine, 319(4), 189-194.
- Wong, L. F., Porter, T. F., & de Jesús, G. R. (2014). Recurrent early pregnancy loss and antiphospholipid antibodies: where do we stand?. *Lupus*, 23(12), 1226-1228.
- Younis, J. S., Ohel, G., Brenner, B., Haddad, S., Lanir, N., & Ben-Ami, M. (2000). The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. *BJOG: An International Journal of Obstetrics & Gynaecology*, 107(3), 415-419.

How to cite this article:

Nisreen K.Al-Bezrah.2015, Antiphospholipid Autoantibodies Testing In Women With Unexplained Infertility And Recurrent First Trimester Abortion. *Int J Recent Sci Res*. 6(10), pp. 6936-6940.

*International Journal of Recent Scientific
Research*

ISSN 0976-3031



9 770576 303009